Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ananta Swargiary, Manita Daimari, Arup Swargiary, Arup Biswas, Dulur Brahma & Hiloljyoti Singha. Identification of phytocompounds as potent inhibitors of sodium/glucose cotransporter-2 leading to diabetes treatment. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-14.
Read now
Read now
Articles from other publishers (43)
I. Stafeev, M. Agareva, S. Michurina, A. Tomilova, E. Shestakova, E. Zubkova, M. Sineokaya, E. Ratner, M. Menshikov, Ye Parfyonova & M. Shestakova. (2024) Semaglutide 6-months therapy of type 2 diabetes mellitus restores adipose progenitors potential to develop metabolically active adipocytes. European Journal of Pharmacology 970, pages 176476.
Crossref
Crossref
Janet B. McGill, Irl B. Hirsch, Christopher G. Parkin, Grazia Aleppo, Carol J. Levy & James R. GavinIIIIII. (2024) The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review. Diabetes Therapy 15:5, pages 1085-1098.
Crossref
Crossref
Divya Devineni, Meleeka Akbarpour, Yufan Gong & Nathan D. Wong. (2022) Inadequate Use of Newer Treatments and Glycemic Control by Cardiovascular Risk and Sociodemographic Groups in US Adults with Diabetes in the NIH Precision Medicine Initiative All of Us Research Program. Cardiovascular Drugs and Therapy 38:2, pages 347-357.
Crossref
Crossref
Janvi Parekh, Himani Shende, Ajay Kumar, Hardeep Singh Tuli & Ginpreet Kaur. (2024) Assessing the Clinical Correlation between Alzheimer's disease and Type-2 Diabetes Mellitus: Current Strategies and Emerging Perspectives. Current Pharmacology Reports 10:2, pages 145-158.
Crossref
Crossref
Justin Wan, Caesar Ferrari & Micheal Tadros. (2024) GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment. Gastroenterology Insights 15:1, pages 191-212.
Crossref
Crossref
Kavishankar Gawli & Kavya Sritha Bojja. (2024) Molecules and targets of antidiabetic interest. Phytomedicine Plus 4:1, pages 100506.
Crossref
Crossref
Huzaifa Ul Haq Ansari, Shurjeel Uddin Qazi, Faiza Sajid, Zahabia Altaf, Shamas Ghazanfar, Naveen Naveed, Amna Shakil Ashfaq, Abdul Hannan Siddiqui, Hamza Iqbal & Sana Qazi. (2024) Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis. Endocrine Practice 30:2, pages 160-171.
Crossref
Crossref
Tigran Makunts, Haroutyun Joulfayan & Ruben Abagyan. (2024) Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System (Preprint). JMIRx Med.
Crossref
Crossref
Maria Zachou, Pagona Flevari, Narjes Nasiri-Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva Kassi & Theodoros Androutsakos. (2023) The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review. European Journal of Clinical Pharmacology 80:1, pages 127-150.
Crossref
Crossref
Shilpa Rajagopal, Faisal Alruwaili, Vasilis Mavratsas, Myrna K Serna, Vijaya L Murthy & Mukaila Raji. (2023) Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Idiopathic Inflammatory Myopathy: From Mechanisms of Action to Clinical Applications. Cureus.
Crossref
Crossref
Sachin M Shridharani & Joshua Kohan. (2024) The Emerging Role of Injectable Weight Loss Medications in Plastic Surgery: A Systematic Review. Aesthetic Surgery Journal 44:1, pages 68-79.
Crossref
Crossref
Chen-Yu Han, Jia-Ping Lu, Xiao-Mei Ye, Hai-Ying Jin, Wei-Wei Xu, Ping Wang & Min Zhang. (2023) Effect of beinaglutide combined with metformin versus aspart 30 with metformin on metabolic profiles and antidrug antibodies in patients with type 2 diabetes: a randomized clinical trial. Frontiers in Endocrinology 14.
Crossref
Crossref
Daisuke Hayashi, Caitlyn Edwards, Jennifer A. Emond, Diane Gilbert-Diamond, Melissa Butt, Andrea Rigby & Travis D. Masterson. (2023) What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients 15:22, pages 4809.
Crossref
Crossref
Magdalena Złotek, Antonina Kurowska, Mariola Herbet & Iwona Piątkowska-Chmiel. (2023) GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy. Biomedicines 11:11, pages 3035.
Crossref
Crossref
Sachi Khemka, Aananya Reddy, Ricardo Isaiah Garcia, Micheal Jacobs, Ruhananhad P. Reddy, Aryan Kia Roghani, Vasanthkumar Pattoor, Tanisha Basu, Ujala Sehar & P. Hemachandra Reddy. (2023) Role of diet and exercise in aging, Alzheimer’s disease, and other chronic diseases. Ageing Research Reviews 91, pages 102091.
Crossref
Crossref
Evangelos Oikonomou, Maria Xenou, George E. Zakynthinos, Paraskevas Tsaplaris, Stamatios Lampsas, Evanthia Bletsa, Ioannis Gialamas, Konstantinos Kalogeras, Athina Goliopoulou, Maria I. Gounaridi, Theodoros Pesiridis, Aikaterini Tsatsaragkou, Manolis Vavouranakis, Gerasimos Siasos & Dimitris Tousoulis. (2023) Novel Approaches to the Management of Diabetes Mellitus in Patients with
Coronary Artery Disease. Current Pharmaceutical Design 29:23, pages 1844-1862.
Crossref
Crossref
Caraline Watkins, Zoe Schilling, Kevin Kawalec & Darrell Hulisz. (2023) Does GLP-RA Plus an SGLT2 Inhibitor Yield Greater Weight Loss in Patients with Obesity and Diabetes than Monotherapy?. Current Cardiovascular Risk Reports 17:9, pages 155-165.
Crossref
Crossref
Anjay Rastogi & Matthew R. Weir. (2023) Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus. Journal of Diabetes and its Complications 37:8, pages 108515.
Crossref
Crossref
Zheng-Rong Ye, Can-Qun Yan, Nianchun Liao & Si-Hua Wen. (2023) The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials. Reproductive Sciences 30:8, pages 2349-2361.
Crossref
Crossref
Abdulrhman Khaity, Nada Mostafa Al-dardery, Khaled Albakri, Omar A. Abdelwahab, Mahmoud Tarek Hefnawy, Yaman A. S. Yousef, Ruaa E. Taha, Sarya Swed, Wael Hafez, Rene Hurlemann & Mohamed E. G. Elsayed. (2023) Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis. Frontiers in Psychiatry 14.
Crossref
Crossref
Shuo Zhang, Chuanyan Zhang, Jingxian Chen, Feiying Deng, Zezhen Wu, Dan Zhu, Fengwu Chen, Yale Duan, Yue Zhao & Kaijian Hou. (2023) Efficacy of polyethylene glycol loxenatide versus insulin glargine on glycemic control in patients with type 2 diabetes: a randomized, open-label, parallel-group trial. Frontiers in Pharmacology 14.
Crossref
Crossref
Peyton W. Moore, Kevin Malone, Delena VanValkenburg, Lauren L. Rando, Brooke C. Williams, Hannah G. Matejowsky, Shahab Ahmadzadeh, Sahar Shekoohi, Elyse M. Cornett & Alan D. Kaye. (2022) GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications. Advances in Therapy 40:3, pages 723-742.
Crossref
Crossref
Braden Millar & Monica de Gaetano. (2023) Posing the rationale for synthetic lipoxin mimetics as an adjuvant treatment to gold standard atherosclerosis therapies. Frontiers in Pharmacology 14.
Crossref
Crossref
Dalia Shami, John M Sousou, Einas Batarseh & Laith Alazrai. (2023) The Roles of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists and Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Decreasing the Occurrence of Adverse Cardiorenal Events in Patients With Type 2 Diabetes. Cureus.
Crossref
Crossref
Fang Zhou, Lu Jiang, Jiamei Guo, Yuting Fan, Qin Pan, Tianlian Li, Xiaoshi Sun & Ping Li. (2023) Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes. Therapeutic Advances in Chronic Disease 14, pages 204062232311615.
Crossref
Crossref
Christian Sümeghy Søndergaard, Paulina Nuñez Esquivel, Maria Dalamaga & Faidon Magkos. (2022) Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes. Current Oncology Reports 25:1, pages 29-40.
Crossref
Crossref
Safaet Alam, Anik Dhar, Muhib Hasan, Fahmida Tasnim Richi, Nazim Uddin Emon, Md. Abdul Aziz, Abdullah Al Mamun, Md. Nafees Rahman Chowdhury, Md. Jamal Hossain, Jin Kyu Kim, Bonglee Kim, Md. Sadman Hasib, S. M. Neamul Kabir Zihad, Mohammad Rashedul Haque, Isa Naina Mohamed & Mohammad A. Rashid. (2022) Antidiabetic Potential of Commonly Available Fruit Plants in Bangladesh: Updates on Prospective Phytochemicals and Their Reported MoAs. Molecules 27:24, pages 8709.
Crossref
Crossref
Rory J. McCrimmon, Philip Home, Alice Cheng, Francesco Giorgino, Vivian Fonseca, Elisabeth Souhami, Agustina Alvarez, Pascaline Picard & Julio Rosenstock. (2022)
Hypoglycaemia events with
iGlarLixi
versus premix biphasic insulin aspart 30 (
BIAsp
30) in people with type 2 diabetes advancing from basal insulin: An analysis of the
SoliMix
trial
. Diabetes, Obesity and Metabolism 24:12, pages 2391-2399.
Crossref
Crossref
Maha Alser & Mohamed A. Elrayess. (2022) From an Apple to a Pear: Moving Fat around for Reversing Insulin Resistance. International Journal of Environmental Research and Public Health 19:21, pages 14251.
Crossref
Crossref
João Pedro Ferreira, Abhinav Sharma, Francisco Vasques‐Nóvoa, António Angélico‐Gonçalves, Ana Rita Leite, Marta Borges‐Canha, Davide Carvalho, Milton Packer, Faiez Zannad, Adelino Leite‐Moreira & João Sérgio Neves. (2022) Albiglutide in patients with type 2 diabetes and heart failure: a post‐hoc analysis from Harmony Outcomes. European Journal of Heart Failure 24:10, pages 1792-1801.
Crossref
Crossref
Ziwan Guan, Yue Du, Rui Li, Shufang Zhang, Yuedong Xu, Xiaoqian Zhang, Fan Zhang, Ying Yin, Kunrong Wu, Xiaoli Li & Yan Li. (2022) Association between glucagon-like peptide-1 receptor gene polymorphism and treatment response to GLP1R agonists in Chinese patients with type 2 diabetes: a prospective cohort study. European Journal of Clinical Pharmacology 78:5, pages 793-799.
Crossref
Crossref
Safaet Alam, Md. Moklesur Rahman Sarker, Taposhi Nahid Sultana, Md. Nafees Rahman Chowdhury, Mohammad A. Rashid, Nusrat Islam Chaity, Chao Zhao, Jianbo Xiao, Elsayed E. Hafez, Shah Alam Khan & Isa Naina Mohamed. (2022) Antidiabetic Phytochemicals From Medicinal Plants: Prospective Candidates for New Drug Discovery and Development. Frontiers in Endocrinology 13.
Crossref
Crossref
Manoj Chawla, Debmalya Sanyal & SupratikC Bhattacharyya. (2022) Glycemic treatment effect of oral semaglutide plus other antidiabetic medications: An Indian experience. Journal of Diabetology 13:4, pages 377.
Crossref
Crossref
E. V. Biryukova & I. V. Solovyeva. (2021) Efficacy of dulaglutide: an evidence-based review of its potential indications. Meditsinskiy sovet = Medical Council:7, pages 18-30.
Crossref
Crossref
Pamela R. Kushner & Davida F. Kruger. (2020) The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring. Clinical Diabetes 38:4, pages 348-356.
Crossref
Crossref
Jiska van Schaik, Dominique G.A. Begijn, Laura van Iersel, Yvonne Vergeer, Eelco W. Hoving, Babette Peeters & Hanneke M. van Santen. (2020) Experiences with Glucagon-Like Peptide-1 Receptor Agonist in Children with Acquired Hypothalamic Obesity. Obesity Facts 13:4, pages 361-370.
Crossref
Crossref
Patrick M. Jedlowski, Charisse H. Te, Robert J. Segal & Maryam T. Fazel. (2018) Cutaneous Adverse Effects of Diabetes Mellitus Medications and Medical Devices: A Review. American Journal of Clinical Dermatology 20:1, pages 97-114.
Crossref
Crossref
Vladimer Darsalia, Thomas Klein, Thomas Nyström & Cesare Patrone. (2018) Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential. Neuropharmacology 136, pages 280-286.
Crossref
Crossref
Renuca Modi, Peter Rye, Sarah Cawsey, Daniel W. Birch & Arya M. Sharma. (2018) Liraglutide Effects on Upper Gastrointestinal Investigations: Implications Prior to Bariatric Surgery. Obesity Surgery 28:7, pages 2113-2116.
Crossref
Crossref
M. E. Trautmann & J. Vora. (2018) Use of glucagon‐like peptide‐1 receptor agonists among individuals on basal insulin requiring treatment intensification. Diabetic Medicine 35:6, pages 694-706.
Crossref
Crossref
Michael E. Trautmann, Luc Van Gaal, Jenny Han & Elise Hardy. (2017) Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials. Journal of Diabetes and its Complications 31:9, pages 1415-1422.
Crossref
Crossref
Jerry Meece. (2017) The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy. Advances in Therapy 34:3, pages 638-657.
Crossref
Crossref
Juan P Frías, Cristian Guja, Elise Hardy, Azazuddin Ahmed, Fang Dong, Peter Öhman & Serge A Jabbour. (2016) Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. The Lancet Diabetes & Endocrinology 4:12, pages 1004-1016.
Crossref
Crossref